Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
CENTOGENE GmbHMay 6, 2021 GMT
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO terms
Release includes increase of almost 19 million to over 31 million unique variants
New features, including variant classification based on ACMG guidelines and streamlined HPO search tools, help to accelerate diagnosis and expand on resources for orphan drug development
New biochemistry module expands on previous genetic testing foundation to further fuel the knowledge base of rare diseases
HPO source code released for free use globally
CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study
March 09, 2021 06:30 ET | Source: CENTOGENE GmbH CENTOGENE GmbH Rostock, GERMANY
Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Significant milestone of 10,000 participants reached
With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Company’s Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointments of Dr. Andrin Oswald as Managing Director and Dr. Jonathan Sheldon as Supervisory Director, the reappointment of Mr. Richard Stoffelen as Managing Director, and adjustments to the compensation of the Supervisory Board.